GlassScriptPhysician profile
Erica Calil
NPI 1407474836
$11,684.90
in general payments reported to CMS, 2019-2025
26 companies · $1,820 in 2025
The $1,820 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,439 · 2022: $2,285 · 2023: $2,572 · 2024: $3,568 · 2025: $1,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,794 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,793.76 |
| Education | $167.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,403.57 | 2022-2025 | Sotyktu |
| Abbvie INC. | $1,367.92 | 2021-2025 | |
| Genzyme Corporation | $1,268.51 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $1,199.15 | 2023-2025 | Zoryve |
| Incyte Corporation | $1,191.49 | 2021-2025 | Opzelura |
| Ucb, INC. | $862.33 | 2022-2024 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $795.02 | 2021-2025 | Tremfya, Simponi, Stelara |
| Janssen Scientific Affairs, LLC | $575.46 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $451.06 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $420.81 | 2021-2025 | Dupixent |
| Amgen INC. | $348.34 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $312.31 | 2023-2025 | Adbry |
| Pfizer INC. | $279.75 | 2021-2024 | |
| Galderma Laboratories, L.P. | $195.06 | 2021-2025 | Aklief, Nemluvio |
| Mayne Pharma Commercial LLC | $160.62 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $153.58 | 2023-2024 | Ycanth |
| Dermavant Sciences, INC. | $142.27 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $132.54 | 2024-2025 | |
| Organon LLC | $125.93 | 2025 | Vtama |
| Almirall LLC | $69.59 | 2024-2025 | Seysara, Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.72 | 2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $64.47 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.16 | 2022-2025 | Cabtreo |
| Organogenesis INC. | $22.49 | 2025 | Apligraf |
| Blueprint Medicines Corporation | $21.25 | 2024 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Calil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.